Pharmacokinetics of Mycophenolic Acid after Intravenous Administration of Mycophenolate Mofetil to Healthy Cats

被引:10
|
作者
Slovak, J. E. [1 ,2 ]
Rivera, S. M. [1 ,2 ]
Hwang, J. K. [1 ,2 ]
Court, M. H. [1 ,2 ]
Villarino, N. F. [1 ,2 ]
机构
[1] Washington State Univ, Coll Vet Med, Dept Vet Clin Sci, Program Individualized Med, Pullman, WA 99164 USA
[2] Washington State Univ, Pullman, WA 99164 USA
来源
JOURNAL OF VETERINARY INTERNAL MEDICINE | 2017年 / 31卷 / 06期
关键词
Cats; Immunosuppressant; Mycophenolate mofetil; Pharmacokinetics; HEART-FAILURE; DOGS; TORSEMIDE; FUROSEMIDE; TORASEMIDE;
D O I
10.1111/jvim.14827
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background: Mycophenolate mofetil (MMF), the prodrug of mycophenolic acid (MPA), is becoming increasingly popular as an alternative immunosuppressant in feline medicine. Pharmacokinetic information is not available for cats. Objective: The purpose of this study was to determine whether MMF is biotransformed into the active metabolite MPA and to evaluate the disposition of MPA after a 2-hour constant rate intravenous (IV) infusion of MMF in healthy cats. Animals: Healthy cats (n = 6). Methods: This was a prospective pilot study. All cats were administered MMF at 20 mg/kg every 12 hours over a 2-hour constant rate infusion for 1 day. The concentrations of MPA and its derivatives in blood were determined using a validated UHPLC-UV method. Results: All cats biotransformed MMF into MPA. The mean AUC(0-14) (h) ranged from 6 to 50 h*mg/L after IV dosing of MMF. Transient large bowel diarrhea was recorded in 2 of 6 cats after medication administration. Conclusion and Clinical Importance: The disposition of MPA in plasma was highly variable, which could result in high interindividual variability in the safety and efficacy of treatment with MMF in cats.
引用
收藏
页码:1827 / 1832
页数:6
相关论文
共 50 条
  • [41] Investigation of the Crossreactivity of Mycophenolic Acid Glucuronide Metabolites and of Mycophenolate Mofetil in the Cedia MPA Assay
    Shipkova, Maria
    Schuetz, Ekkehard
    Besenthal, Ingo
    Fraunberger, Peter
    Wieland, Eberhard
    THERAPEUTIC DRUG MONITORING, 2010, 32 (01) : 79 - 85
  • [42] Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation
    Zucker, K
    Tsaroucha, A
    Olson, L
    Esquenazi, V
    Tzakis, A
    Miller, J
    THERAPEUTIC DRUG MONITORING, 1999, 21 (01) : 35 - 43
  • [43] PHARMACOKINETICS OF D(+)-USNIC ACID IN RABBITS AFTER INTRAVENOUS ADMINISTRATION
    VENKATARAMANA, D
    KRISHNA, DR
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1993, 18 (02) : 161 - 163
  • [44] Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats
    Carnes, Michelle Brogan
    Axlund, Todd W.
    Boothe, Dawn M.
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2011, 72 (09) : 1247 - 1252
  • [45] Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects
    Anderson, GD
    Elmer, GW
    Kantor, ED
    Templeton, IE
    Vitiello, MV
    PHYTOTHERAPY RESEARCH, 2005, 19 (09) : 801 - 803
  • [46] Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration
    Lacroix, M
    Donati, F
    Varin, F
    ANESTHESIOLOGY, 1997, 86 (02) : 322 - 330
  • [47] Pharmacokinetics of Mycophenolic Acid and Its Glucuronide Metabolites in Stable Adult Liver Transplant Recipients With Renal Dysfunction on a Low-Dose Calcineurin Inhibitor Regimen and Mycophenolate Mofetil
    Beckebaum, Susanne
    Armstrong, Victor W.
    Cicinnati, Vito Rosario
    Streit, Frank
    Klein, Christian Georg
    Gerken, Guido
    Paul, Andreas
    Oellerich, Michael
    THERAPEUTIC DRUG MONITORING, 2009, 31 (02) : 205 - 210
  • [48] PHARMACOKINETICS OF REC-HIRUDIN IN HEALTHY-VOLUNTEERS AFTER INTRAVENOUS ADMINISTRATION
    CARDOT, JMA
    LEFEVRE, GY
    GODBILLON, JA
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1994, 22 (02): : 147 - 156
  • [49] Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis
    Daudén, E
    Sánchez-Peinado, C
    Ruiz-Genao, D
    García-F-Villalta, M
    Onate, MJ
    García-Díez, A
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (01) : 132 - 135
  • [50] Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil
    Lidgate, D
    Brandl, M
    Holper, M
    Abubakari, A
    Wu, XY
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2002, 28 (10) : 1275 - 1283